HOXA9 and acute myeloid leukemia: To validate the anti-leukemic effect of PHD inhibition on AML cells transformed by drivers independent of the MLL/Meis1/Hoxa9 axis, we employed murine AML cells harboring FLT3-ITD mutations (with and without NPM1 mutations), PML-RARα and AML1-ETO.